Gunagratinib
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 19, 2018 (NCT03758664)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
- Fibroblast growth factor receptor 2INHIBITOR
FGFR2 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05678270 | Phase 2 | Nov 15, 2022 | Beijing InnoCare Pharma Tech Co., Ltd., Huazhong University of Science and Technology |
| NCT05372120 | Phase 2 | Dec 15, 2021 | Beijing InnoCare Pharma Tech Co., Ltd., Peking University |
| NCT04565275 | Phase 1/Phase 2 (Phase 2) | Sep 14, 2020 | Beijing InnoCare Pharma Tech Co., Ltd. |
| NCT04492293 | Phase 2 | May 27, 2020 | Beijing InnoCare Pharma Tech Co., Ltd. |
| NCT03758664 | Phase 1 | Dec 19, 2018 | Beijing InnoCare Pharma Tech Co., Ltd., Huazhong University of Science and Technology |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing InnoCare Pharma Tech Co., Ltd. | For profit | 5 | 5 | 2 | 2018 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 0 | 2 | 2018 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1